Following ICI addition to the RT, the antitumor response was enhanced by restoring exhausted CD8+ TIL activity and increasing the CD8+ T cell/Treg ratio in several mouse tumor models as compared to those of the control groups (63). This evidence concerns the gene CD8A and neoplasm.